|
|
| OvaSave® | Currently, OvaSave® is being evaluated (Clinical Trial) to treat Crohn's disease patients which resist to conventional treatments.
OvaSave® treatment is an infusion bag containing autologous anti-ovalbumin Tr1 cells which have been produced thanks to TxCell's manufacturing process. The expanded population of autologous Tr1 cell clones will be injected intravenously in the patient.
OvaSave® will have to be administered to patients in a period of active inflammation. | Product |
OvaSave®: Autologous anti-ovalbumin
type 1 T regulatory lymphocytes
|
Concept
|
OvaSave® is an investigational product in a new class of autologous cellular immunotherapy that is uniquely designed to regulate the patient's own immune system.
OvaSave® holds promise because it may provide patients meaningful clinical benefits with low toxicity.
| | Indications |
Inflammatory Bowel Diseases (IBD):
Crohn's disease and Ulcerative Colitis
| | Clinical Phase |
|
Market |
TxCell's main aim is to enable the feasibility of its Crohn's treatment to benefit to all moderate to severe patients.
At present, OvaSave® is the only new product in clinical development specifically addressing the issue of autologous cell therapy, which allows the treatment of all patients relapsing conventional treatments. (Approximately 64% of Crohn's disease patients are moderate to severe). Overall prevalence of IBD in the seven major markets is estimated to be nearly 1.8 million (700 000 for Crohn's disease and 1.1 million for Ulcerative Colitis). |
Collaboration
|
Co-development, research and out-licensing
agreements are available
|
|
|
|
